Overview

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

Phase:

Phase 2

Details

Lead Sponsor:

Nasser Hanna, M.D.

Collaborators:

Hoosier Cancer Research Network
Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab